Palvella Names John D. Doux to Board to Advance QTORIN™ Rare Disease Pipeline
Palvella Therapeutics has appointed dermatologist and biotech investor John D. Doux, M.D., M.B.A., to its board to leverage his 20+ years’ clinical experience advancing rare skin disease therapies and the QTORIN™ platform. His orphan dermatology advocacy and QTORIN™ program leadership will accelerate trials in lymphatic, venous malformations.
1. Appointment Details
Palvella Therapeutics has appointed John D. Doux, M.D., M.B.A., to its Board of Directors. Dr. Doux will advise on the expansion of Palvella’s QTORIN™ platform and overall rare skin disease pipeline.
2. Dr. John D. Doux Background
Dr. Doux is a board-certified dermatologist with over 20 years in clinical practice and biotech investing. He authored a 2015 editorial advocating orphan disease models in dermatology and has served on multiple biotech boards.
3. Strategic Implications
Dr. Doux’s deep patient-care perspective and investment insight are expected to strengthen development of QTORIN™ rapamycin and pitavastatin programs. His leadership aims to accelerate clinical trials targeting lymphatic and venous malformations.